Depression and Outcomes of Methadone and Buprenorphine Treatment Among People with Opioid Use Disorders: A Literature Review

References

• Agosti, V., Nunes, E., & Ocepeck-Welikson, K. (1996). Patient factors related to early attrition from an outpatient cocaine research clinic. The American Journal of Drug and Alcohol Abuse, 22(1), 29–39. doi:10.3109/00952999609001643
   PubMed Web of Science ®Google Scholar
• Alterman, A., Rutherford, M., Cacciola, J., McKay, J. & Woody, G. (1996). Response to methadone maintenance and counselling in antisocial patients with and without major depression. Journal of Nervous and Mental Disease, 184(11), 695–702. doi:10.1097/00005053-199611000-00007
   PubMed Web of Science ®Google Scholar
• Anand, D., Paquette, C., Bartuska, A., & Daughters S. B. (2019). Substance type moderates the longitudinal association between depression and substance use from pretreatment through a 1-year follow-up. Drug and Alcohol Dependence, 197, 87–94. doi:10.1016/j.drugalcdep.2019.01.002
   PubMed Web of Science ®Google Scholar
• Andersson H. W., Wenaas M., & Nordfjaern, T. (2018). Relapse after inpatient substance use treatment: A prospective cohort study among users of illicit substances. Addictive Behaviors, 90, 222–228. doi:10.1016/j.addbeh.2018.11.008
   PubMed Web of Science ®Google Scholar
• Arendt, M., Munk-Jorgensen, P., Sher, L., & Jensen, S. O. (2010). Mortality among individuals with cannabis, cocaine, amphetamine, MDMA, and opioid use disorders: A nationwide follow-up study of Danish substance users in treatment. Drug and Alcohol Dependence, 114(2-3), 134–139. doi:10.1016/j.drugalcdep.2010.09.013
   PubMed Web of Science ®Google Scholar
• Avants, S., Warburton, L., & Margolin, A. (2000). The influence of coping and depression on abstinence from illicit drug use in methadone-maintained patients. The American Journal of Drug and Alcohol Abuse, 26(3), 399–416. doi:10.1081/ADA-100100252
   PubMed Web of Science ®Google Scholar
• Bakken, K., Landheim, A., & Vaglum, P. (2007). Axis I and II disorders as long-term predictors of mental distress: A six-year prospective follow-up of substance-dependent patients. BMC Psychiatry, 7(1), 29. doi:10.1186/1471-244X-7-29
   PubMedGoogle Scholar
• Benningfield, M., Dietrich, M., Jones, H., Kaltenbach, K., Heil, S., Stine, S. M., … Fischer, G. (2012). Opioid dependence during pregnancy: Relationships of anxiety and depression symptoms to treatment outcomes. Addiction, 107(S1), 74–82. doi:10.1111/j.1360-0443.2012.04041.x
   PubMedGoogle Scholar
• Berkowitz, B. (1976). The relationship of pharmacokinetics to pharmacological activity: Morphine, methadone and naloxone. Clinical Pharmacokinetics, 1(3), 219–230. doi:10.2165/00003088-197601030-00004
   PubMedGoogle Scholar
• Birnbaum, H., White, A., Schiller, M., Waldman, T., Cleveland, J., & Roland, C. (2011). Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Medicine, 12(4), 657–667. doi:10.1111/j.1526-4637.2011.01075.x
   PubMed Web of Science ®Google Scholar
• Brewer, D., Catalano, R., Haggerty, K., Gainey, R., & Fleming, C. (1998). A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction, 93(1), 73–92. doi:10.1046/j.1360-0443.1998.931738.x
   PubMed Web of Science ®Google Scholar
• Brienza, R. S., Stein, M. D., Chen, M., Gogineni, A., Sobota, M., Maksad, J., … Clarke, J. (2000). Depression among needle exchange program and methadone maintenance clients. Journal of Substance Abuse and Treatment, 18(4), 331–337. doi:10.1016/S0740-5472(99)00084-7
   PubMed Web of Science ®Google Scholar
• Brooner, R., King, V., Kidorf, M., Schmidt, C., & Bigelow, G. (1997). Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Archives of General Psychiatry, 54(1), 71–80. doi:10.1001/archpsyc.1997.01830130077015
   PubMed Web of Science ®Google Scholar
• Carrieri, M., Amass, L., Lucas, G., Vlahov, D., Wodak, A., & Woody, G. (2006). Buprenorphine use: The international experience. Clinical Infectious Disease, 43(4), S197–S215. doi:10.1086/508184
   PubMed Web of Science ®Google Scholar
• Carrieri, M. P., Rey, D., Loundou, A., Lepeu, G., Sobel, A., & Obadia, Y. (2003). Evaluation of buprenorphine maintenance treatment in a French cohort of HIV-infected injecting drug users. Drug & Alcohol Dependence, 72(1), 13–21. doi:10.1016/S0376-8716(03)00189-3
   PubMed Web of Science ®Google Scholar
• Charney, D., Palacios-Boix, J., Negrete, J., Dobkin, P., & Gill, K. (2005). Association between concurrent depression and anxiety and six-month outcome of addiction treatment. Psychiatric Services, 56(8), 927–933. doi:10.1176/appi.ps.56.8.927
   PubMed Web of Science ®Google Scholar
• Comer, S., Sullivan, M., Vosburg, S., Manubay, J., Amass, L., Cooper, Z., … Kleber, H. (2010). Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction, 105(4), 709–718. doi:10.1111/j.1360-0443.2009.02843.x
   PubMed Web of Science ®Google Scholar
• Compton, W., Jones, C., & Baldwin, G. (2016). Relationship between nonmedical prescription-opioid use and heroin use. New England Journal of Medicine, 374(2), 154–163. doi:10.1056/NEJMra1508490
   PubMed Web of Science ®Google Scholar
• Cornelius, J., Salloum, I., Mezzich, J., Cornelius, M., Fabrega, H., Ehler, J., … Mann, J. (1995). Disproportionate suicidality in patients with comorbid major depression and alcoholism. The American Journal of Psychiatry, 152(3), 358–364. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/7864260
   PubMed Web of Science ®Google Scholar
• Dagenhardt, L., Bucello, C., Mathers, B., Briegleb, C., Ali, H., Hickman, M., & Mclaren, H. (2011). Mortality among regular or dependent users of heroin and other opioids: A systematic review and meta anlaysis of cohort studies. Addiction, 106(1), 32–51. doi:10.1111/j.1360-0443.2010.03140.x
   PubMed Web of Science ®Google Scholar
• Dean, A., Bell, J., Christie, M., & Mattick, R. (2004). Depressive symptoms during buprenorphine vs. methadone maintenance: Findings from a randomised, controlled trial in opioid dependence. European Psychiatry, 19(8), 510–513. doi:10.1016/j.eurpsy.2004.09.002
   PubMed Web of Science ®Google Scholar
• Dixit, A. R., & Crum, R. M. (2000). Prospective study of depression and the risk of heavy alcohol use in women. American Journal of Psychiatry, 157(5), 751–758. doi:10.1176/appi.ajp.157.5.751
   PubMed Web of Science ®Google Scholar
• Dreifuss, J. A., Griffin, M. L., Frost, K., Fitzmaurice, G. M., Potter, J. S., Fiellin, D. A., … Weiss, R. D. (2013). Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. Drug & Alcohol Dependence, 131(1-2), 112–118. doi:10.1016/j.drugalcdep.2012.12.010
   PubMed Web of Science ®Google Scholar
• El Hage, C., Ghabrash, M. F., Dubreucq, S., Brissette, S., Lespérance, F., Lespérance, P., … Jutras-Aswad, D. (2018). A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder. International Clinical Psychopharmacology, 33(5), 268–273. doi:10.1097/YIC.0000000000000223
   PubMed Web of Science ®Google Scholar
• Evans, D. (2002). Systematic reviews of interpretive research: Interpretive data synthesis of processed data. Australian Journal of Advanced Nursing, 20(2), 22–26. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/12537149
   PubMedGoogle Scholar
• Farre, M., Mas, A., Torrens, M., Moreno, V., & Cami, J. (2002). Retention rate and illicit opioid use during methadone maintenance interventions: A meta-analysis. Drug and Alcohol Dependence, 65(3), 283–290. doi:10.1016/S0376-8716(01)00171-5
   PubMed Web of Science ®Google Scholar
• Ferri, M. R., Finlayson, A. J., Wang, L., & Martin, P. R. (2014). Predictive factors for relapse in patients on buprenorphine maintenance. The American Journal on Addictions, 23(1), 62–67. doi:10.1111/j.1521-0391.2013.12074.x
   PubMed Web of Science ®Google Scholar
• Finch, J. W., Kamien, J. B., & Amass, L. (2007). Two-year experience with buprenorphine-naloxone (Suboxone) for maintenance treatment of opioid dependence within a private practice setting. Journal of Addiction Medicine, 1(2), 104–110. doi:10.1097/ADM.0b013e31809b5df2
   PubMed Web of Science ®Google Scholar
• Fisch, A., Patch, V., Greenfield, A., Raynes, A., McKenna, G., & Levine, M. (1973). Depression and self-concept as variables in the differential response to methadone maintenance combined with therapy. Proceedings of National Conference on Methadone Treatment. 1, 440–446. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/4808182
   Google Scholar
• Gerra, G., Borella, F., Zaimovic, A., Moi, G., Bussandri, M., Bubici, C., & Bertacca, S. (2004). Buprenorphine versus methadone for opioid dependence: Predictor variables for treatment outcome. Drug and Alcohol Dependence, 75(1), 37–45. doi:10.1016/j.drugalcdep.2003.11.017
   PubMed Web of Science ®Google Scholar
• Gerra, G., Leonardi, C., D’amore, A., Strepparola, G., Fagetti, R., Assi, C., … Lucchini, A. (2006). Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30(2), 265–272. doi:10.1016/j.pnpbp.2005.10.007
   PubMed Web of Science ®Google Scholar
• Grant, B. (1995). Comorbidity between DSM-IV drug use disorders and major depression: Results of a national survey of adults. Journal of Substance Abuse, 7(4), 481–497. doi:10.1016/0376-8716(95)01160-4
   PubMedGoogle Scholar
• Greenfield, S., Weiss, R., Muenz, L., Vagge, L., Kelly, J., Bello, L., & Michael, J. (1998). The effect of depression on return to drinking: A prospective study. Archives of General Psychiatry, 55(3), 259–265. doi:10.1001/archpsyc.55.3.259
   PubMed Web of Science ®Google Scholar
• Havard, A., Teesson, M., Darke, S., & Ross, J. (2006). Depression among heroin users: 12-month outcomes from the Australian Treatment Outcome Study (ATOS). Journal of Substance Abuse Treatment, 30(4), 355–362. doi:10.1016/j.jsat.2006.03.012
   PubMed Web of Science ®Google Scholar
• Joe, G., Brown, B., & Simpson, D. (1995). Psychological problems and client engagement in methadone treatment. Journal of Nervous and Mental Disease, 183(11), 704–710. doi:10.1097/00005053-199511000-00006
   PubMed Web of Science ®Google Scholar
• Kadden, R., Kranzler, H., & Rounsaville, B. (1995). Validity of the distinction between “substance‐induced” and “independent” depression and anxiety disorders. The American Journal on Addictions, 4(2), 107–117. doi:10.1111/j.1521-0391.1995.tb00441.x
   Web of Science ®Google Scholar
• Kessing, L. (1999). The effect of comorbid alcoholism on recurrence in affective disorder: A case register study. Journal of Affective Disorders, 53(1), 49–55. doi:10.1016/S0165-0327(98)00095-0
   PubMed Web of Science ®Google Scholar
• Kokkevi, A., Stefanis, N., Anastasopoulou, E., & Kostogianni, C. (1998). Personality disorders in drug abusers: Prevalence and their association with Axis I disorders as predictors of treatment retention. Addictive Behaviors, 23(6), 841–853. doi:10.1016/S0306-4603(98)00071-9
   PubMed Web of Science ®Google Scholar
• Kosten, T., Falcioni, J., Oliveto, A., & Feingold, A. (2004). Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone. The American Journal on Addictions, 13(2), 191–201. doi:10.1080/10550490490435966
   PubMed Web of Science ®Google Scholar
• Kosten, T., Morgan, C., & Kosten, T. (1990). Depressive symptoms during buprenorphine treatment of opioid abusers. Journal of Substance Abuse Treatment, 7(1), 51–54. doi:10.1016/0740-5472(90)90035-o
   PubMed Web of Science ®Google Scholar
• Kosten, T., Rounsaville, B., & Kleber, H. (1986). A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts. Archives of General Psychiatry, 43(8), 733–738. doi:10.1001/archpsyc.1986.01800080019003
   PubMed Web of Science ®Google Scholar
• Kranzler, H., & Liebowitz, N. (1988). Anxiety and depression in substance abuse: Clinical implications. Medical Clinics of North America, 72(4), 867–885. doi:10.1016/S0025-7125(16)30749-0
   PubMed Web of Science ®Google Scholar
• Laqueille, X., Poirier, M., Jalfre, V., Bourdel, M., Willard, D., & Olié, J. (2001). Facteurs prédictifs de la réponse à la buprénorphine en traitement substitutif des héroïnomanies: Résultats d’une étude multicentrique sur 73 patients [Predictive factors of response to buprenorphine in the substitutive treatment of heroin addicts: Results of a multicenter study of 73 patients]. La Presse Médicale, 30(32), 1581–1585. Retrieved from https://www.em-consulte.com/en/article/91936
   PubMed Web of Science ®Google Scholar
• Manhapra, A., Rosenheck, R., & Fiellin, D. (2017). Opioid substitution treatment is linked to reduced risk of death in opioid use disorder. British Medical Journal, 357, j1947. doi:10.1136/bmj.j1947
   PubMedGoogle Scholar
• Mark, T., Woody, G., Juday, T., & Kleber, H. (2001). The economic costs of heroin addiction in the United States. Drug and Alcohol Dependence, 61(2), 195–206. doi:10.1016/S0376-8716(00)00162-9
   PubMed Web of Science ®Google Scholar
• Marsch, L., Stephens, M., Mudric, T., Strain, E., Bigelow, G., & Johnson, R. (2005). Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Experimental and Clinical Psychopharmacology, 13(4), 293–302. doi:10.1037/1064-1297.13.4.293
   PubMed Web of Science ®Google Scholar
• Milby, J. B., Conti, K., Wallace, D., Mennemeyer, S., Mrug, S., & Schumacher, J. E. (2015). Comorbidity effects on cocaine dependence treatment and examination of reciprocal relationships between abstinence and depression. Journal of Consulting and Clinical Psychology, 83(1), 45–55. doi:10.1037/a0037960
   PubMed Web of Science ®Google Scholar
• Moffett, L., & Radenhausen, R. (1990). Assessing depression in substance abusers: Beck depression inventory and SCL-90R. Addictive Behaviors, 15(2), 179–181. doi:10.1016/0306-4603(90)90023-Q
   PubMed Web of Science ®Google Scholar
• Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Medicine, 6(7), e1000097. doi:10.1371/journal.pmed.1000097
   PubMed Web of Science ®Google Scholar
• Moore, B., Fiellin, D., Barry, D., Sullivan, L., Chawarski, M., O’Connor, P., & Schottenfeld, R. (2007). Primary care office-based buprenorphine treatment: Comparison of heroin and prescription opioid dependent patients. Journal of General Internal Medicine, 22(4), 527–530. doi:10.1007/s11606-007-0129-0
   PubMed Web of Science ®Google Scholar
• Morris, D. H., Davis, A. K., Lauritsen, K. J., Rieth, C. M, Sivestri, M. M., Winters, J. J.,& Chemack, S. T. (2018). Substance use consequences, mental health problems, and readiness to change among veterans seeking substance use treatment. Journal of Substance Abuse Treatment, 94, 113–121. doi:10.1016/j.jsat.2018.08.005
   PubMed Web of Science ®Google Scholar
• Oderda, G., Lake, J., Rudell, K., Roland, C., & Masters, E. (2015). Economic burden of prescription opioid misuse and abuse: A systematic review. Journal of Pain and Palliative Care Pharmacotherapy, 29(4), 388–400. doi:10.3109/15360288.2015.1101641
   PubMedGoogle Scholar
• Pani, P., Maremmani, I., Pirastu, R., Tagliamonte, A., & Gessa, G. (2000). Buprenorphine: A controlled clinical trial in the treatment of opioid dependence. Drug and Alcohol Dependence, 60(1), 39–50. doi:10.1016/S0376-8716(00)80006-X
   PubMed Web of Science ®Google Scholar
• Pedrelli, P., Iovieno, N., Vitali, M., Tedeschini, E., Bentley, K., & Papakostas, G. (2011). Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: A meta-analysis. Journal of Clinical Psychopharmacology, 31(5), 582–586. doi:10.1097/JCP.0b013e31822c0adf
   PubMed Web of Science ®Google Scholar
• Pettinati, H. M., Oslin, D. W., Kampman, K. M., Dundon, W. D., Xie, H., Gallis, T. L., … O’Brien, C. P. (2010). A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. The American Journal of Psychiatry, 167(6), 668–675. doi:10.1176/appi.ajp.2009.08060852
   PubMed Web of Science ®Google Scholar
• Poirier, M., Laqueille, X., Jalfre, V., Willard, D., Bourdel, M., Fermanian, J., & Olié, J. (2004). Clinical profile of responders to buprenorphine as a substitution treatment in heroin addicts: Results of a multicenter study of 73 patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 28(2), 267–272. doi:10.1016/j.pnpbp.2003.10.003
   PubMed Web of Science ®Google Scholar
• Popay J, Roberts, H., Sowden A, petticrew M, Arai L, Roders M., … Duffy, S. (2006). Guidance on the conduct of narrative synthesis in systematic reviews. Lancaster, UK: Lancaster University.
   Google Scholar
• Rao, S., Broome, K., & Simpson, D. (2004). Depression and hostility as predictors of long‐term outcomes among opiate users. Addiction, 99(5), 579–589. doi:10.1111/j.1360-0443.2004.00686.x
   PubMed Web of Science ®Google Scholar
• Ross, J., Teesson, M., Darke, S., Lynskey, M., & Ali, R. (2005). The characteristics of heroin users entering treatment: Findings from the Australian Treatment Outcome Study (ATOS). Drug and Alcohol Review, 24(5), 411–418. doi:10.1080/09595230500286039
   PubMed Web of Science ®Google Scholar
• Rounsaville, B., Kosten, T., Weissman, M., & Kleber, H. (1986). Prognostic significance of psychopathology in treated opiate addicts: A 2.5-year follow-up study. Archives of General Psychiatry, 43(8), 739–745. doi:10.1001/archpsyc.1986.01800080025004
   PubMed Web of Science ®Google Scholar
• Rounsaville, B., Weissman, M., Kleber, H., & Wilber, C. (1982). Heterogeneity of psychiatric diagnosis in treated opiate addicts. Archives of General Psychiatry, 39(2), 161–166. doi:10.1001/archpsyc.1982.04290020027006
   PubMed Web of Science ®Google Scholar
• Rounsaville, B. J., Weissman, M. M., Crits, C. K., Wilber, C., & Kleber, H. (1982). Diagnosis and symptoms of depression in opiate addicts: Course and relationship to treatment outcome. Archives of General Psychiatry, 39(2), 151–156. doi:10.1001/archpsyc.1982.04290020021004
   PubMed Web of Science ®Google Scholar
• Ruetsch, C. (2010). Empirical view of opioid dependence. Journal of Managed Care Pharmacy, 16(1), S9–S13. doi:10.18553/jmcp.2010.16.S1-B.9
   PubMed Web of Science ®Google Scholar
• Scherbaum, N., & Specka, M. (2008). Factors influencing the course of opiate addiction. International Journal of Methods in Psychiatric Research, 17(1), S39–S44. doi:10.1002/mpr.244
   PubMedGoogle Scholar
• Schuckit, M. A. (2016). Treatment of opioid-use disorders. The New England Journal of Medicine, 375(16), 357–368. doi:10.1056/NEJMra1604339
   PubMedGoogle Scholar
• Simpson, D. D., & Joe, G. W. (1993). Motivation as a predictor of early dropout from drug abuse treatment. Psychotherapy: Theory, Research, Practice, Training, 30(2), 357–368. doi:10.1037/0033-3204.30.2.357
   Web of Science ®Google Scholar
• Stein, M. (1999). Medical consequences of substance abuse. The Psychiatric Clinics of North America, 22(2), 351–370. doi:10.1016/S0193-953X(05)70081-2
   PubMed Web of Science ®Google Scholar
• Stein, M. D., Herman, D. S., Kettavong, M., Cioe, P. A., Friedmann, P. D., Tellioglu, T., & Anderson, B. J. (2010). Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. Journal of Substance Abuse Treatment, 39(2), 157–166. doi:10.1016/j.jsat.2010.05.014
   PubMed Web of Science ®Google Scholar
• Subramaniam, G., Warden, D., Minhajuddin, A., Fishman, M., Stitzer, M., Adinoff, B., … Woody, G. (2011). Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth. Journal of the American Academy Child and Adolescent Psychiatry, 50(11), 1120–1128. doi:10.1016/j.jaac.2011.07.010
   PubMed Web of Science ®Google Scholar
• Sullivan, L., Fiellin, D., & O’Connor, P. (2005). The prevalence and impact of alcohol problems in major depression: A systematic review. American Journal of Medicine, 118(4), 330–341. doi:10.1016/j.amjmed.2005.01.007
   PubMed Web of Science ®Google Scholar
• Tenore, P. (2008). Psychotherapeutic benefits of opioid agonist therapy. Journal of Addictive Diseases, 27(3), 49–65. doi:10.1080/10550880802122646
   PubMed Web of Science ®Google Scholar
• Villafranca, S., McKellar, J., Trafton, J., & Humphreys, K. (2006). Predictors of retention in methadone programs: A signal detection analysis. Drug and Alcohol Dependence, 83(3), 218–224. doi:10.1016/j.drugalcdep.2005.11.020
   PubMed Web of Science ®Google Scholar